Charles River Laboratories Intl. Inc vs Yum China Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Yum China Holdings Inc trades at $42.92 (market cap $14.11B). The key difference: Charles River Laboratories Intl. Inc and Yum China Holdings Inc are close in size by market cap, and Yum China Holdings Inc pays a 2.78% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Yum China Holdings Inc for 77 Days on average.
| CRL | YUMC | |
|---|---|---|
Market Cap | $14.23B | $14.11B |
Volume | 1,176,885 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $57.95 |
52-Week Low | $149.93 | $39.98 |
Typical Hold Time | 33 Days | 77 Days |
Enterprise Value | $17.06B | $15.02B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
YUMC trades at $42.92, up 5.58% today, with strong analyst support (73.68% buy ratings) but technical indicators show bearish momentum. The company demonstrates solid fundamentals with consistent revenue growth from $9.6B in 2022 to $11.8B in 2025, and net income improving to $929M. Recent strategic moves include the $1.2B acquisition of Pizza Hut China brand ownership and expansion of Pizza Hut Burger Bars to 300 locations.
YUMC presents a value opportunity with reasonable valuation (P/E 15.3, P/S 1.2) and strong profitability (ROE 17.5%), though technical weakness and China economic exposure pose near-term risks. The stock's 25.6% analyst upside potential and consistent earnings beats support long-term growth prospects despite current bearish technical signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →